Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years

Yu, Xu-ya; Chen, Zhiping; Wang, S Y; Pan, Huirong; Wang, Zhifang; Zhang, Qiu-Fen; Shen, Lingzhi; Zheng, Xiaoping; Yan, Chuanfu; Lu, Mei; Chen, Bo; Zheng, Yali; Zhang, Jun; Lv, Huakun; Huang, Shou-Jie

doi:10.1016/j.vaccine.2019.04.006

Cited by 25 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This dosage regimen can be recommended for travellers visiting an HEV‐endemic regions or used during an HEV outbreak. In addition, another clinical study (Clinical trial.gov; ID: NCT02417597) conducted in healthy adults >65 years of age concluded that Hecolin ® , with protective efficacy of 96%, is safe and well‐tolerated 139 . These clinical trials were conducted in China, where HEV‐4 is the most predominant circulating genotype.…”

Section: Vaccinesmentioning

confidence: 99%

Hepatitis E: An update on One Health and clinical medicine

Velavan

Pallerla

Johne

et al. 2021

Liver International

View full text Add to dashboard Cite

The hepatitis E virus (HEV) is one of the main causes of acute hepatitis and the de facto global burden is underestimated. HEV‐related clinical complications are often undetected and are not considered in the differential diagnosis. Convincing findings from studies suggest that HEV is clinically relevant not only in developing countries but also in industrialized countries. Eight HEV genotypes (HEV‐1 to HEV‐8) with different human and animal hosts and other HEV‐related viruses are in circulation. Transmission routes vary by genotype and location, with large waterborne outbreaks in developing countries and zoonotic food‐borne infections in developed countries. An acute infection can be aggravated in pregnant women, organ transplant recipients, patients with pre‐existing liver disease and immunosuppressed patients. HEV during pregnancy affects the fetus and newborn with an increased risk of vertical transmission, preterm and stillbirth, neonatal jaundice and miscarriage. Hepatitis E is associated with extrahepatic manifestations that include neurological disorders such as neuralgic amyotrophy, Guillain‐Barré syndrome and encephalitis, renal injury and haematological disorders. The risk of transfusion‐transmitted HEV is increasingly recognized in Western countries where the risk may be because of a zoonosis. RNA testing of blood components is essential to determine the risk of transfusion‐transmitted HEV. There are currently no approved drugs or vaccines for HEV infections. This review focuses on updating the latest developments in zoonoses, screening and diagnostics, drugs in use and under development, and vaccines.

show abstract

Section: Vaccinesmentioning

confidence: 99%

Hepatitis E: An update on One Health and clinical medicine

Velavan

Pallerla

Johne

et al. 2021

Liver International

View full text Add to dashboard Cite

show abstract

“…While the vaccine has not yet gained approval in other countries, in 2020, the Norwegian Institute of Public Health completed recruitment for a phase IV study investigating the efficacy of the vaccine in pregnant women in Bangladesh (NCT02759991) [ 134 ]. A recent clinical trial in China also demonstrated the safety of the vaccine in those over 65 years old [ 135 ]. A National Institute of Allergy and Infectious Diseases (NIAID)-sponsored phase I study in the United States is ongoing (NCT03827395).…”

Section: Hevmentioning

confidence: 99%

A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis

et al. 2021

View full text Add to dashboard Cite

The global burden of viral hepatitis remains substantial despite advances in antiviral therapy and effective vaccines. There are five hepatitis viruses (hepatitis A, B, C, D, and E). Mortality related to hepatitis B virus and hepatitis C virus infections is among the top four global infectious diseases, together with human immunodeficiency virus infection, malaria, and tuberculosis. Of those deaths, approximately 47% are attributable to hepatitis B virus, 48% to hepatitis C virus and the remainder to hepatitis A virus and hepatitis E virus. Ending hepatitis epidemics as a major public health threat is feasible with the tools and approaches currently available. Effective vaccines are available for preventing viral hepatitis A, B and E infections. New oral, well-tolerated treatment regimens for chronic hepatitis C patients can achieve cure rates of over 90%. Effective treatment is also available for people with chronic hepatitis B virus infection; although for most people such treatment needs to be long-term, and recent advanced aim at a "functional cure" of hepatitis B. In this review article, we discuss the most recent advances of the diagnosis and treatment of viral hepatitis.

show abstract

“…It acts as a nanoparticle against HEV infection 77 . A study carried out in China reported that antibody loss is significantly lower for innate immunity compared to immunity acquired from vaccination after 10 years 78 . The recombinant VLP-based Hecolin ® HEV vaccine available in China acts as a trivalent vaccine.…”

Section: Hev Vaccine Efficacymentioning

confidence: 99%

Hepatitis E vaccines: A mini review

Ahmad¹,

Haroon

Ahmad

et al. 2021

Biomed. Res. Ther.

View full text Add to dashboard Cite

The hepatitis E virus (HEV) is an important public health concern and a significant cause of enterically-transmitted viral hepatitis infections. HEV infection remains a serious threat to life, especially in immunocompromised individuals and pregnant women. Globally, vaccines have had a massive impact on public health and saved millions of lives. Vaccination can reduce the healthcare expenditure, decrease the mortality rate, and increase life expectancy. The availability of commercially effective vaccines is the most effective means for the prevention of HEV. However, the development of classic inactive or attenuated HEV vaccines is not feasible due to the lack of an efficient cell culture system for HEV. In recent years, recombinant HEV vaccine approaches have been explored. Many vaccine candidates have showed potential efficacy against HEV infection. Currently, the only licensed vaccine is Hecolin ® , a recombinant vaccine developed by Xiamen Innovax Biotech Co., Ltd. It is available in China. However, there are many hindrances when it comes to the acrossthe-board application of Hecolin ® and other vaccines worldwide. Large-scale efforts are needed to further evaluate the efficacy and safety of Hecolin ® in at-risk populations and to pass the World Health Organization prequalification for licensing outside of China.

show abstract

Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years

Cited by 25 publications

References 13 publications

Hepatitis E: An update on One Health and clinical medicine

Hepatitis E: An update on One Health and clinical medicine

A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis

Hepatitis E vaccines: A mini review

Contact Info

Product

Resources

About

Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years

Cited by 25 publications

References 13 publications

Hepatitis E: An update on One Health and clinical medicine

Hepatitis E: An update on One Health and clinical medicine

A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis

Hepatitis E vaccines: A mini review

Contact Info

Product

Resources

About

Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65 years